Abstract
The drugs for the treatment of ADHD are the amphetamine psychostimulants (methylphenidate and lysdexamphtamine, propharmacin of dexamethetamine) and atomoxetine, which is a selective inhibitor of the norepinephrine collection. In recent years, the consumption of psycho-stimulant drugs for the treatment of ADHD has grown considerably. Between 6 and 10% of young people treated with methylphenidate or lysdexamphthalmine and 15% of atomoxetine treatments present at some time of treatment some type of cardiovascular adverse effect (especially hypertension and tachycardia).
Keywords
Cardiac risks; Psycho-stimulating drugs; ADHD
Bibliographic citation
Riscos cardíacs de metilfenidat, atomoxetina i lisdexamfetamina en nens i joves amb TDAH. Barcelona: Servei Català de la Salut; 2016.
Audience
Professionals
Use this identifier for quote and/or link this document
https://hdl.handle.net/11351/3339This item appears in following collections
The following license files are associated with this item: